Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: prearranged (2), prepared (1000), planned (748), ordered (441), controlled (1000), structured (191)

Back to school poster June 2020

Description: BACK TO SCHOOL With schools beginning to gradually reopen, it brings a period of change for young people, preparing to transition
Url: /Media/UHS-website-2019/Docs/Services/Child-health/COVID-19/Back-to-school-poster-June-2020.pdf

Twitter guidelines for #PPIimpact tweetchat

Description: New to twitter? Twitter is an online news and social networking site where people communicate in short messages called tweets. ‘Tweeting
Url: /Media/Southampton-Clinical-Research/PPI/Twitter-guidelines-for-PPIimpact-tweetchat.docx

How to look after yourself after heart surgery (Easy Read) - patient information

Description: This Easy Read factsheet contains important information for people who have had heart surgery at Southampton General Hospital.
Url: /Media/UHS-website-2019/Patientinformation/Heartandlungs/How-to-look-after-yourself-after-heart-surgery-Easy-Read-4061-PIL.pdf

Papers CoG 29.04.2025 v2

Description: Date Time Location Chair Agenda Council of Governors 29/04/2025 14:00 - 15:45 Conference Room, Heartbeat/Microsoft Teams Jenni
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-29.04.2025-v2.pdf

Atezolizumab (1875mg 21-days) SC

Description: Chemotherapy Protocol UROTHELIAL CANCER Atezolizumab SC (1875mg – 21 days) Regimen • Urothelial cancer – Atezolizumab monotherapy (1st or 2nd line) Indications • First line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab-SC-1875mg-21-days.pdf

Patient-initiated follow-up (PIFU) for thyroid cancer - patient information

Description: This factsheet contains a summary of patient-initiated follow-up (PIFU) for thyroid cancer.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Patient-initiated-follow-up-PIFU-for-thyroid-cancer-3672-PIL.pdf

Cemiplimab

Description: Chemotherapy Protocol SKIN CANCER Cemiplimab (350mg) Regimen  Skin – Cemiplimab (350mg) Indication  Metastatic or locally advanced cutaneous squamous cell carcinoma in patients
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Cemiplimab.pdf

Enhanced recovery after anti-reflux surgery - patient information

Description: This factsheet is designed to help increase your understanding of the enhanced recovery programme, and to enable you and your family
Url: /Media/UHS-website-2019/Patientinformation/Surgery/Enhanced-recovery-after-anti-reflux-surgery-3319-PIL.pdf

Endometrial-Dostarlimab

Description: Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological diagnosis of endometrial carcinoma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Durvalumab_14day

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

101 to 110 of 192

Previous … 9 10 11 12 13 … Next